Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VBI Vaccines Inc VBIVQ

Healthcare Biotechnology
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The... see more

Recent & Breaking News (PINL:VBIVQ)

Brii Biosciences and VBI Vaccines Present Positive Data from Completed Phase 1b/2a Study on BRII-179 (VBI-2601) in Patients with Chronic Hepatitis B at the International Liver Congress 2021

Business Wire June 23, 2021

VBI Vaccines to Present at Upcoming Scientific Conferences

Business Wire June 17, 2021

VBI Vaccines Announces Results of Annual General Meeting

Business Wire June 9, 2021

VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021

Business Wire June 9, 2021

VBI Vaccines Granted FDA Fast Track Designation for VBI-1901 for the Treatment of Recurrent GBM

Business Wire June 8, 2021

VBI Vaccines to Participate in Upcoming Investor Conferences

Business Wire June 1, 2021

VBI Vaccines Closes Second Tranche of $12 Million Debt Financing

Stockhouse Editorial May 21, 2021

VBI Vaccines Announces $12 Million Second Tranche of Debt Financing with K2 HealthVentures

Business Wire May 21, 2021

VBI Vaccines to Present Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at 2021 ASCO Annual Meeting

Business Wire May 20, 2021

VBI Vaccines Announces Publication of Results from Pivotal Phase 3 Study, PROTECT, of VBI's Prophylactic 3-Antigen Hepatitis B Vaccine Candidate in The Lancet Infectious Diseases

Business Wire May 12, 2021

VBI Vaccines Announces First Quarter 2021 Financial Results and Provides Corporate Update

Business Wire May 10, 2021

VBI Vaccines Announces Multiple Presentations at the Canadian Liver Meeting 2021

Business Wire May 3, 2021

VBI Vaccines Announces Publication of Preclinical and Challenge Study Data of its eVLP Vaccine Candidate Against COVID-19 (VBI-2902)

Business Wire April 28, 2021

VBI Vaccines to Participate in National Securities Corporation's Biotech Investor Summit

Business Wire April 27, 2021

VBI Vaccines Announces Presentation at the 2021 Annual Conference on Vaccinology Research

Business Wire April 26, 2021

Brii Biosciences, Vir Biotechnology and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

GlobeNewswire April 21, 2021

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

Business Wire April 21, 2021

VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate 

Business Wire April 12, 2021

VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference

Business Wire March 15, 2021

CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants

Business Wire March 10, 2021